Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
16/08/2024 13:00
* Bolt Biotherapeutics Inc BOLT.OQ reported a quarterly
adjusted
loss of 46 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -48 cents. The mean expectation of
five analysts for the quarter was for a loss of 48 cents per
share. Wall Street expected results to range from -66 cents
to -36 cents per share.
* Revenue fell 11% to $1.28 million from a year ago;
analysts
expected $891.50 thousand.
* Bolt Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 56 cents.
* The company reported a quarterly loss of $21.2 million.
* Bolt Biotherapeutics Inc shares had fallen by 7.9% this
quarter and lost 38.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
Wall Street's median 12-month price target for Bolt
Biotherapeutics Inc is $1.50
This summary was machine generated from LSEG data August 16 at
12:00 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.48 -0.46 Beat
Mar. 31 2024 -0.51 -0.28 Beat
Dec. 31 2023 -0.48 -0.47 Beat
Sep. 30 2023 -0.50 -0.43 Beat